Skip to content
Log in
Open access

Unraveling the impact of trip12 on neurodevelopment: insights from a zebrafish model

Maider Roibás-Santos P. Suarez‐Bregua J. Rotllant Ángel Carracedo Catarina Allegue L. Sánchez A. Blanco-Hortas A. Pensado-López
Jul 2026 · Brain Communications · Vol 8 · 0 citations · 75 references
Medicine

TL;DR

This study provides substantial evidence for the vital role of trip12 in the early stages of development, as homozygous individuals exhibited early mortality by Day 23 post-fertilization, while a substantial mortality rate was observed by Day 35 in ‘heterozygous’ mutants.

Abstract

Abstract Thyroid Hormone Receptor Interactor 12 (TRIP12) is an E3 ubiquitin ligase capable of mediating ubiquitin-dependent proteolysis of specific protein substrates. This function regulates key biological processes, including cell cycle progression, cell differentiation, chromatin remodelling and DNA damage repair. Consequently, loss-of-function mutations in TRIP12 have been associated with a broad spectrum of human diseases, including cancer and neurological and neurodevelopmental disorders. Previous studies have demonstrated that pathological variants of TRIP12 cause Clark–Baraitser syndrome, characterized by craniofacial dysmorphism, motor delay and intellectual disability, with or without autism spectrum disorder. Despite the well-characterized clinical manifestations, the underlying molecular pathways affected by TRIP12 disruption and their implication in the pathophysiology of autism spectrum disorder and intellectual disability remain unclear. Using a knock-out zebrafish model, we have elucidated the essential role of trip12 in diverse metabolic and biological pathways, particularly those related to neural and neurodevelopmental processes, shedding light on potential mechanisms underlying the pathogenesis. Heterozygous and recessive homozygous zebrafish mutants exhibit clinical features analogous to those observed in human patients, including craniofacial anomalies and decreased locomotor activity. Furthermore, this study provides substantial evidence for the vital role of trip12 in the early stages of development, as homozygous individuals exhibited early mortality by Day 23 post-fertilization, while a substantial mortality rate of 90% was observed by Day 35 in ‘heterozygous’ mutants. The present study demonstrates the profound impact that trip12 mutations have on embryogenesis, and transcriptomic analysis offers an in-depth knowledge of the molecular basis of the disease. These findings offer valuable insights into potential therapeutic targets for improving outcomes in individuals with TRIP12-associated disorders.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Jun 2026

GIT1 loss of function causes a recognizable syndromic neurodevelopmental disorder.

Evidence is provided that biallelic GIT1 variants affecting transcript processing or causing premature termination underlie a syndromic neurodevelopmental disorder and an essential role for GIT1 in development and cognitive function is established.

P. Failla, V. Muto, Antonella Lauri et al. · 0 citations
Jul 2026

Neurodevelopmental alterations are key drivers of SPG56.

Combined transcriptomics profiling in cyp2u1-/- zebrafish and SPG56 patient iPSC-derived cortical neurons supports impaired neural network development as a key disease mechanism.

D. Galatolo, Devid Damiani, V. Naef et al. · 0 citations
Review Jul 2026

DYRK1A Signaling in the Brain: Molecular Mechanisms and Neurotransmitter Regulation.

DYRK1A exemplifies precision medicine for dosage-sensitive genes where therapeutic success depends on restoring physiological balance, and Species divergence between rodent and human iPSC models, combined with inter-individual variability, underscores the limitations of current mechanistic models.

Sampriti Paul, Sonal Dubey, Prashant Tiwari · 0 citations
Open access Jul 2026

Further characterization of the BRSK2-associated neurodevelopmental disorder.

Variants in BRSK2, encoding brain specific kinase-2, have recently been associated with an autosomal dominant neurodevelopmental disorder (NDD). We have assembled 52 cases with heterozygous BRSK2 variants and variable neurodevelopmental phenotypes with frequent neuropsychiatric and behavioral symptoms. The variant spectrum included 15 different truncating variants, seven (potential) splice variants, three structural variants, and 12 different missense variants. Of the missense variants, seven were in the kinase domain, and the others in the UBA and the KA1 domain or outside domains. Variants occurred de novo in 19 cases and were inherited in 18. We utilized Drosophila melanogaster as a model and assessed viability and performed climbing and bang sensitivity assays upon knockdown of the fly orthologue sff or upon overexpression of wildtype or mutant human BRSK2. Pan-neuronal knockdown of sff resulted in impaired locomotor behavior and seizure susceptibility. Ubiquitous or pan-neuronal overexpression of human wildtype BRSK2 in Drosophila resulted in lethality or locomotor impairment, respectively, indicating toxicity. Overexpressing mutant BRSK2 did not or incompletely affect viability and locomotor behavior for six of seven tested kinase domain missense variants and one KA1 domain variant, indicating a (partial) loss-of-function effect. Interestingly, overexpressing BRSK2 with the remaining missense variant from the kinase domain and the two most C-terminal missense variants resulted in possible gain of function. Our findings further delineate the clinical and molecular spectrum of BRSK2-associated NDD and provide further insights into the role of BRSK2/sff in nervous system function and dysfunction.

Palak Singhal, Tzung-Chien Hsieh, Nadja Ehmke et al. · 0 citations